Key facts
- It has raised $2.6M; the latest was Seed Round in Jun 2025.
- Notable investors include Winvest Venture Capital, Yuhan.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for SL Bigen
- ·The full record, as it builds
Funding rounds
No funding rounds for SL Bigen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SL Bigen
Developer of bio-genetic drugs designed to focus on cell-based therapies by developing innovative biologics. The company specializes in developing mesenchymal stem cell lines and natural killer cells targeting cancer and neurodegenerative diseases, enabling healthcare providers to save patients lives through advanced cellular therapies.
- Sector
- Healthcare
- HQ
- Incheon, South Korea
- Website
- slbigen.com/
- Ownership
- Privately Held (backing)
SL Bigen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SL Bigen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SL Bigen in its N-PORT filings yet. We sweep new filings monthly.